PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms.
PEP-010, first CP&IP-based drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile. PEP-010 is entering Phase Ia/b clinical trials for the treatment of advanced solid tumors in partnership with Institut Curie and Gustave Roussy, two leading European cancer centers.
PEP-Therapy, which was founded in 2014 and builds on research from Sorbonne University and Institut Curie, is backed by international investors: Seventure Partners, Italian Angels for Growth, Doorway, Magna Capital Partner, Business Angels des Grandes Ecoles (BAdGE), and by Dr Bernard Majoie, former Chairman and CEO of Laboratoires Fournier, Founding Chairman of Fournier-Majoie Foundation for Innovation (FFMI).